drugset / Trial / NCT02873351

A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration

NCT02873351 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

From 3 large patient databases, patients diagnosed with AMD who have never taken levodopa(L-DOPA) containing medications have a mean age of diagnosis at 71 years. Patients who have been treated with L-DOPA containing medications have a mean age of diagnosis of AMD at 79 years. L-DOPA binds to GPR143 in the retinal pigment epithelium, and releases PEDF, which protects the retina and downregulates VEGF, which is the cause of neovascularization. The Investigators will evaluate the safety and tolerability of carbidopa-levodopa in patients with AMD, and measure the effects on surrogate functional biomarkers of AMD.

Timeline

Start
2019-09
Primary completion
2020-12
Completion
2020-12

Outcome

Outcome not reported

Stopped: “Decided to do studies in patients with AMD”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbidopa Unknown 25 mg —
Subject Levodopa Unknown 100 mg —